Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Breast Self Examination

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44379   clinical trials with a EudraCT protocol, of which   7391   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    33 result(s) found for: Breast Self Examination. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2019-002635-28 Sponsor Protocol Number: 69081 Start Date*: 2019-10-14
    Sponsor Name:University Medical Center Utrecht
    Full Title: The effect of hyperbaric oxygen therapy on breast cancer patients with late radiation toxicity
    Medical condition: Late radiation toxicity
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002323-38 Sponsor Protocol Number: GBG105GeparPiPPa Start Date*: 2022-08-29
    Sponsor Name:German Breast Group
    Full Title: A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K inhibitor inavolisib in patients with HER2-positive, HR-pos...
    Medical condition: Patients with early breast cancer
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005575-12 Sponsor Protocol Number: BYON5667.002 Start Date*: 2021-06-30
    Sponsor Name:Byondis B.V.
    Full Title: A multicenter, randomized, double-blind, placebo-controlled trial with a single arm run-in period to evaluate the safety and efficacy of sodium thiosulfate (BYON5667) eye drops to reduce ocular tox...
    Medical condition: Single arm run-in period: Patients with solid tumours (excluding gastric tumours and adenocarcinomas of the gastroesophageal junction) Randomized part of the study: patients with locally advanced ...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001161-16 Sponsor Protocol Number: ML28879 Start Date*: 2013-09-12
    Sponsor Name:ROCHE SPA
    Full Title: NATIONAL PHASE IIIB PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI-CENTRE, OPEN LABEL STUDY TO ASSESS THE SAFETY OF SUBCUTANEOUS TRASTUZUMAB AND MOLECULAR BIOMARKERS IN PATIENTS WITH EARLY AND LOCAL...
    Medical condition: EARLY AND LOCALLY ADVANCED HER2-POSITIVE BREAST CANCER
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000158-36 Sponsor Protocol Number: OXYPEP202 Start Date*: 2016-03-18
    Sponsor Name:PEPTONIC medical AB
    Full Title: A Phase 2b, Double-blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the 12-week Efficacy of Vagitocin in Postmenopausal Women with Symptoms of Vulvovaginal Atrophy
    Medical condition: Vaginal Atrophy
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004872 10047782 Vulvovaginal atrophy LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003395-13 Sponsor Protocol Number: KOA-21-02 Start Date*: 2022-03-03
    Sponsor Name:Bioventus LLC
    Full Title: A Multiple Arm, Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase 2 Study of Intra-Articular Administration of an Allogeneic Human Placental Tissue Particu...
    Medical condition: Osteoarthritis of the knee
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004859 10023476 Knee osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001027-40 Sponsor Protocol Number: ERIBRAIN-IPC2017-014 Start Date*: 2018-09-11
    Sponsor Name:Institut Paoli-Calmettes
    Full Title: ERIBRAIN - A phase II study of Eribulin in brain metastases from HER2-negative breast cancer pre-treated with anthracyclines and taxanes
    Medical condition: HER2-negative breast cancer with brain metastases
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-003835-18 Sponsor Protocol Number: GE-135-004 Start Date*: 2009-04-21
    Sponsor Name:GE Healthcare Ltd
    Full Title: A phase 2, open-label test-retest study to assess the reproducibility of quantitative measurements of 18F uptake by solid tumours using PET imaging following intravenous administration of AH111585 ...
    Medical condition: Adult subjects with solid primary or metastatic tumours 2 cm or more in diameter. Malignancies may include but are not limited to non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), gl...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004010-17 Sponsor Protocol Number: ANG206 Start Date*: 2004-12-09
    Sponsor Name:Amersham plc and its Amersham Health affiliates, trading as GE Healthcare
    Full Title: An open-label, multi-centre, phase 2a study to assess the feasibility and safety of intravenous bolus administration of 99mTc-NC100692 Injection in imaging metastases in late stage cancer patients.
    Medical condition: The subjects to be included in this study have been diagnosed with primary breast, lung (non-small cell), ovarian or prostate cancer or malignant melanoma and have metastatic spread of the cancer t...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GB (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-000382-32 Sponsor Protocol Number: REP0121 Start Date*: 2021-08-16
    Sponsor Name:Dompé farmaceutici s.p.a.
    Full Title: A multicenter, randomized, double-blind, placebo-controlled phase 2 study to assess the efficacy and safety of oral reparixin in cancer related fatigue in patients with locally advanced or metastat...
    Medical condition: Cancer related fatigue in patients with locally advanced or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004864 10082262 Chemotherapy fatigue LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004267-40 Sponsor Protocol Number: MIT-Es0001-C202 Start Date*: 2017-01-16
    Sponsor Name:Estetra SPRL
    Full Title: A SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, TWO-ARM STUDY TO EVALUATE THE OVARIAN FUNCTION INHIBITION OF A MONOPHASIC COMBINED ORAL CONTRACEPTIVE (COC) CONTAINING 15 MG ESTETROL (E4) AND 3 MG DROSPIRE...
    Medical condition: Hormonal contraception in woman seeking contraception
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004865 10073728 Hormonal contraception LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-004937-15 Sponsor Protocol Number: BNC210.006 Start Date*: 2015-04-16
    Sponsor Name:BIONOMICS LIMITED
    Full Title: A randomized, double-blinded, placebo and lorazepam-controlled, four-way crossover, Phase II study to evaluate the effects of single oral administration of BNC210 on brain activity changes captured...
    Medical condition: Generalized Anxiety Disorder
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004873 10018105 Generalized anxiety disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-001289-14 Sponsor Protocol Number: MIT-Do001-C301 Start Date*: 2020-02-05
    Sponsor Name:Estetra SRL
    Full Title: A Randomized Double-blind Placebo Controlled Phase 3 Trial to evaluate the Efficacy and Safety of Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comf...
    Medical condition: Moderate to Severe Vasomotor Symptoms (VMS) in Postmenopausal Women
    Disease: Version SOC Term Classification Code Term Level
    21.0 10047065 - Vascular disorders 10020407 Hot flashes LLT
    Population Age: Adults Gender: Female
    Trial protocol: PL (Completed) GB (GB - no longer in EU/EEA) SK (Completed) HU (Completed) LT (Completed) CZ (Completed) ES (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2005-000402-32 Sponsor Protocol Number: EU-CCBE-2003 Start Date*: 2005-06-07
    Sponsor Name:Genetronics Biomedical Corporation
    Full Title: An open-label study using the MedPulser Elektroporation System to treat cutaneous & subcutaneous foci of cancer
    Medical condition: Histologically confirmed recurrent SCC, recurrent BCC, Melanoma, Adenocarcinoma (i.e., local recurrence of breast cancer), Merkel Cell Carcinoma, Cutaneous Lymphoma, other subcutaneous solid tumors...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-000716-30 Sponsor Protocol Number: RGL-003-001 Start Date*: 2020-09-10
    Sponsor Name:Gedeon Richter Plc.
    Full Title: A randomized, double-blind, placebo-controlled, multicenter, proof-of-concept study to evaluate a combined oral contraceptive (COC) containing 30 µg ethinylestradiol and 150 µg levonorgestrel plus ...
    Medical condition: Hypoactive sexual desire disorder (HSDD) secondary to combined oral contraception use.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10020933 Hypoactive sexual desire disorder LLT
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed) BG (Completed) PL (Completed) CZ (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2013-000829-31 Sponsor Protocol Number: ML28878 Start Date*: 2013-10-10
    Sponsor Name:Roche Nederland B.V.
    Full Title: A LOCAL, OPEN LABEL, MULTICENTRE, PHASE IIIB STUDY, INVESTIGATING SUBCUTANEOUS TRASTUZUMAB ADMINISTERED AT HOME WITH SINGLE INJECTION DEVICE IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER
    Medical condition: HER2-positive early breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-013333-24 Sponsor Protocol Number: EMR 701048-525 Start Date*: 2009-08-03
    Sponsor Name:MERCK SERONO SPA
    Full Title: Multicenter, open-label, 12 weeks Phase IV study to assess adherence to treatment in relapsing multiple sclerosis (RMS) subjects switching from other injectable DMDs using ReBiSmart to self-inje...
    Medical condition: RELAPSING MULTIPLE SCLEROSIS
    Disease: Version SOC Term Classification Code Term Level
    12.0 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002078-23 Sponsor Protocol Number: M06-829 Start Date*: 2006-10-12
    Sponsor Name:Abbott GmbH & Co. KG (Abbott)
    Full Title: A Multi-Center, Open-Label Study of the Fully Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects with Moderate to Severe Crohn's Disease.
    Medical condition: Moderate to severe Crohn's Disease (Harvey Bradshaw Index score greater or equal to7).
    Disease: Version SOC Term Classification Code Term Level
    8.1 10013099 Disease Crohns LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) NO (Completed) FI (Completed) PT (Completed) SK (Completed) DE (Completed) IE (Completed) DK (Completed) FR (Completed) AT (Completed) GB (Completed) SE (Completed) GR (Completed) CZ (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-006199-39 Sponsor Protocol Number: 310523 Start Date*: 2007-07-05
    Sponsor Name:Bayer AB, Bayer Schering Pharma
    Full Title: A double-blind, randomized, multi-center study to investigate the endometrial safety of a continuous, combined, oral estrogen/progestin preparation (0.5 mg 17b-estradiol [E2] / 0.25 mg drospirenone...
    Medical condition: Women suffering from postmenopausal symptoms
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050903 Postmenopausal symptoms LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002821-32 Sponsor Protocol Number: FENDEEP Start Date*: 2021-12-09
    Sponsor Name:Neurologia Aplicada, SLP
    Full Title: The FENDEEP Study: Fenfluramine for the treatment of different types of developmental and epileptic encephalopathies: a pilot trial exploring epileptic and non-epileptic outcomes.
    Medical condition: Five different types of developmental and epileptic encephalopathies (DEEs): SYNGAP1 and STXBP1 encephalopathies, inv-dup(15) encephalopathy, multifocal or bilateral Malformations of Cortical Devel...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10053551 Intractable epilepsy LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Feb 09 06:09:18 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA